|1.||de Andrade, Sérgio Faloni: 3 articles (11/2012 - 07/2009)|
|2.||Cechinel Filho, Valdir: 3 articles (11/2012 - 07/2009)|
|3.||Vilegas, Wagner: 3 articles (03/2006 - 09/2002)|
|4.||Toma, Walber: 3 articles (12/2004 - 09/2002)|
|5.||Carvalho, André Lopes: 2 articles (05/2015 - 02/2007)|
|6.||Lemos, Marivane: 2 articles (02/2010 - 07/2009)|
|7.||Gandolfi, Renan Becker: 2 articles (02/2010 - 07/2009)|
|8.||Hirota, Christina L: 2 articles (04/2009 - 11/2006)|
|9.||McKay, Derek M: 2 articles (04/2009 - 11/2006)|
|10.||Silverman, Sol: 2 articles (07/2006 - 02/2004)|
11/01/1979 - "We report on 3 patients with vesical malacoplakia who were treated successfully with bethanechol chloride."
10/01/1980 - "Re: malacoplakia of the bladder: efficacy of bethanechol chloride therapy."
04/01/1980 - "Re: malacoplakia of the bladder: efficacy of bethanechol chloride therapy."
11/01/1979 - "Malacoplakia of the bladder: efficacy of bethanechol chloride therapy."
09/01/1986 - "A second patient is described with the syndrome of hypogammaglobulinaemia and malakoplakia; he too responded dramatically to bethanechol treatment and remains well on it."
|2.||Gastroesophageal Reflux (GERD)
08/01/1993 - "The similar action of the two H2-antagonists appears to suggest that their effect on salivation is connected probably with the cholinergic activity and it is concluded that the combination of bethanechol with these blockers may improve the esophageal clearance, an action that may be beneficial in the treatment of the gastroesophageal reflux disease."
12/01/1985 - "These results fail to show that bethanechol is more effective than antiacids in controlling gastroesophageal reflux; moreover, bethanechol is more difficult to administer and offers a higher rate of undesired side effects."
03/01/1975 - "Recently cholinergic stimulation of the lower esophageal sphincter (LES) with bethanechol has been shown to be effective in the treatment of chronic gastroesophageal reflux. "
12/01/1985 - "To compare the efficacy of bethanechol in the treatment of gastroesophageal reflux with that of antiacids, a prospective, cross-over study was undertaken, in which 20 affected infants and children were randomized into two groups on 6-week alternate bethanechol and antiacids oral medication. "
07/01/1986 - "Thus, this study demonstrates a failure of the acute administration of bethanechol to improve postprandial gastroesophageal reflux and raises the issue of whether the widespread use of bethanechol to treat reflux in children is appropriate."
06/01/1982 - "These results fail to show that the addition of bethanechol to an intensive antacid regimen is more effective than the antacid regimen alone in the treatment of erosive esophagitis and that patients with esophagitis and normal lower esophageal sphincter pressures respond more favorably to medical treatment."
06/01/1982 - "Double-blind controlled trial of bethanechol and antacid versus placebo and antacid in the treatment of erosive esophagitis."
06/01/1982 - "To determine the value of bethanechol in the treatment of erosive esophagitis, a double-blind study was undertaken in which 28 patients were randomized to either bethanechol and antacid, or placebo and antacid. "
07/01/1976 - "In contrast, the sphincter response to bethanechol during esophagitis was not different from the preperfusion response and remained unchanged after resolution of the esophagitis. "
03/01/1975 - "Since chronic reflux and esophagitis also occur in patients with vagotomy and antrectomy, we studied the effect of bethanechol on sphincter pressure in 10 patients who had had vagotomy and antrectomy. "
06/15/1991 - "Treatment with metoclopramide hydrochloride and bethanechol chloride resulted in improved attitude, appetite, Schirmer tear test response, and decrease in frequency of vomiting within 24 hours. "
09/01/2006 - "The authors describe complete remission of recurrent postprandial discomfort, nausea, and vomiting within 1 week of starting mirtazapine in a gastroparetic patient who had failed to respond, in 7 months, to conventional prokinetics (erythromycin, metoclopramide, domperidone, perphenazine, itopride, bethanechol, and/or tegaserod) and pyloric injection of botulinum toxin. "
01/01/2013 - "Strikingly, tumor volume per animal was increased 52% in bethanechol-treated compared with control mice (179.7 ± 21.0 vs. 111. "
01/01/2013 - "When euthanized at week 20, control mice had 8.0 ± 1.3 tumors per animal, whereas bethanechol-treated mice had 10.4 ± 1.5 tumors per mouse (mean ± SE; P = 0.023), a 30% increase. "
02/01/2007 - "The use of bethanechol during RT for HNC cancer was associated with significantly higher WRS immediately after RT (p=0.03) in comparison to a similar cohort of patients who had not received bethanechol."
05/01/2011 - "Bethanechol chloride for the prevention of bladder dysfunction after radical hysterectomy in gynecologic cancer patients: a randomized controlled trial study."
12/01/1991 - "Bethanechol stimulated a dose-dependent colonic contraction, which was less in the strips from patients with colitis compared with cancer (P less than 0.02) or diverticular disease (P less than 0.05). "
|1.||Ascorbic Acid (Vitamin C)
|2.||Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)
|9.||Botulinum Toxins (Botulinum Toxin)
|10.||Vitamin A (Retinol)